Program
levacetylleucine
Its studies are mostly in Ataxia Telangiectasia · Spinocerebellar Ataxias · Niemann-Pick Disease, Type C, led by IntraBio.
Furthest: phase 3, since Dec 6, 20213 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| IntraBio | 33 open or running | phase 3since Dec 6, 2021 | Dec 6, 2021 | Dec 31, 2027phase 3 · NCT06673056 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 6, 2021First study: phase 3 study in Niemann-Pick Disease, Type CFirst studyNCT05163288 · 53 planned · United States, Australia, Czechia and more
- Oct 31, 2024Phase 3 study in Ataxia TelangiectasiaNCT06673056 · 60 enrolled · United States, Germany, Slovakia and more
- Oct 24, 2025Phase 3 study in Spinocerebellar AtaxiasNCT07221292 · 60 enrolled · United States, Austria, Germany and more
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Ataxia TelangiectasiaNCT06673056
- May 1, 2028Primary completion: phase 3 study in Spinocerebellar AtaxiasNCT07221292
- Jun 12, 2030Primary completion: phase 3 study in Niemann-Pick Disease, Type CNCT05163288
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07221292Spinocerebellar Ataxias · United States, Austria, Germany and more | 3 | Active, not recruiting | May 1, 2028 | 60 |
| NCT06673056Ataxia Telangiectasia · United States, Germany, Slovakia and more | 3 | Active, not recruiting | Dec 31, 2027 | 60 |
| NCT05163288Niemann-Pick Disease, Type C · United States, Australia, Czechia and more | 3 | Recruiting | Jun 12, 2030 | 53 |
How it is read
Names in the registry
- “N-Acetyl-L-Leucine”, 3 entries
Conditions, from the studies’ own filings
- Ataxia Telangiectasia, 1 study
- Spinocerebellar Ataxias, 1 study
- Niemann-Pick Disease, Type C, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.